BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vor Bio readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Vor Bio's drugs run\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07249632-5453@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Telitacicept: Phase 3 readout est. (NCT07249632)
DESCRIPTION:Telitacicept\, phase 3.\nStudy: A Study of Telitacicept in Pati
 ents With Ocular Myasthenia Gravis (OMG)\nEstimated primary completion: 31
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telit
 acicept#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07249632
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456580-5453@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Telitacicept: Phase 3 readout est. (NCT06456580)
DESCRIPTION:Telitacicept\, phase 3\, Generalized Myasthenia Gravis.\nStudy:
  A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravi
 s (UPSTREAM MG)\nEstimated primary completion: March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/telitacicept#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06456580
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07404865-5453@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Telitacicept: Phase 3 readout est. (NCT07404865)
DESCRIPTION:Telitacicept\, phase 3\, Sjögren's Disease.\nStudy: Phase 3 St
 udy of Telitacicept in Active Primary Sjögren's Disease\nEstimated primar
 y completion: December 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/telitacicept#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07404865
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07495033-5453@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Telitacicept: Phase 3 readout est. (NCT07495033)
DESCRIPTION:Telitacicept\, phase 3.\nStudy: Phase III Clinical Trial of Tel
 itacicept Injection in the Treatment of Patients With Connective Tissue Di
 sease-related Interstitial Lung Disease\nEstimated primary completion: 31 
 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telitacicep
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 495033
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
